Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs belantamab mafodotin for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) Meeting Abstract
| Authors: | Moreau, P.; Usmani, S. Z.; van de Donk, N. W. C. J.; Garfall, A. L.; Delforge, M.; Oriol, A.; Nooka, A.; RosinĚol, L.; Bahlis, N.; Otero, P. R.; Martin, T. G.; Diels, J.; Van Sanden, S.; Pei, L.; Ammann, E.; Chastain, K.; Marshall, A.; Slavcev, M.; Londhe, A.; Krishnan, A. |
| Abstract Title: | Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs belantamab mafodotin for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) |
| Meeting Title: | ISPOR Europe 2023 |
| Journal Title: | Value in Health |
| Volume: | 26 |
| Issue: | 12 Suppl. |
| Meeting Dates: | 2023 Nov 12-15 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 1098-3015 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2023-12-01 |
| Start Page: | S5 |
| End Page: | S6 |
| Language: | English |
| ACCESSION: | WOS:001137279500020 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jval.2023.09.028 |
| Notes: | Meeting Abstract: P20 -- Source: Wos |
